IPP Bureau
Novartis to acquire Mariana Oncology for upfront US$ 1 billion
By IPP Bureau - May 03, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Moderna posts Q1 2024 revenues at US$167 million
By IPP Bureau - May 03, 2024
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
FDA grants full approval for TIVDAK to treat cervical cancer
By IPP Bureau - May 02, 2024
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine
By IPP Bureau - May 02, 2024
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024
By IPP Bureau - May 02, 2024
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
By IPP Bureau - May 02, 2024
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
Philips Respironics agrees to pay $1.1 billion settlement after CPAP machine recall
By IPP Bureau - May 01, 2024
Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data
By IPP Bureau - May 01, 2024
The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
By IPP Bureau - May 01, 2024
2024 full-year revenue guidance raised by US$ 2 billion
Granules India announced ANDA Approval for Colchicine Capsules
By IPP Bureau - May 01, 2024
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Lonza launches AI-enabled Route Scouting Service to accelerate small molecule development
By IPP Bureau - April 30, 2024
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Gland Pharma appoints Satnam Singh Loomba as COO
By IPP Bureau - April 29, 2024
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Gland Pharma receives approval for cetrorelix acetate for injection
By IPP Bureau - April 29, 2024
AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment
By IPP Bureau - April 29, 2024
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
Glenmark receives ANDA approval for acetaminophen and ibuprofen tablets
By IPP Bureau - April 29, 2024
Glenmark’s Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg (OTC), will be distributed in the U.S. by Glenmark Therapeutics, USA
